TABLE 3.
Multivariable multilevel model assessing predictors of quality of life in the EUROHIS-QOL tool (QOL) in the study population
| Adjusted for age, sex and if receiving treatment, the time between interview and treatment initiation | Multivariable analysis | |||
| Difference in score (95% CI) | p-value | Difference in score (95% CI) | p-value | |
| TB new (MDR)# | −5.19 (−6.05–−4.34) | <0.0001 | −4.67 (−5.52–−3.81) | <0.0001 |
| TB new (non-MDR)# | −4.11 (−4.41–−3.81) | <0.0001 | −3.84 (−4.15–−3.54) | <0.0001 |
| TB 6 months treatment (MDR)¶ | −3.32 (4.47–−2.17) | <0.0001 | −3.04 (−4.19–−1.89) | <0.0001 |
| TB 6 months treatment (non-MDR)¶ | −1.17 (−2.06–−0.27) | 0.01 | −0.89 (−1.79–0.004) | 0.05 |
| TB carer+ | −0.76 (−1.08–−0.44) | <0.0001 | −0.71 (−1.02–−0.39) | <0.0001 |
| TB previously§ | −0.39 (−0.74–−0.03) | 0.03 | −0.2 (−0.55–0.16) | 0.3 |
| TB neverƒ | Reference | Reference | ||
| Age (for every 10 years) | −0.35 (−0.43–−0.27) | <0.0001 | ||
| Female | −1.08 (−1.31–−0.85) | <0.0001 | ||
| Less than secondary education | −0.80 (−1.2–−0.44) | <0.0001 | −0.56 (−0.91–−0.22) | 0.001 |
| HIV | −3.19 (3.95–−2.43) | <0.0001 | −1.81 (−2.52–−1.08) | <0.0001 |
| Drug use | −2.91 (−3.41–−2.41) | <0.0001 | −1.94 (−2.42–−1.46) | <0.0001 |
| Days between interview and treatment initiation## | 0.003 (0.0006–0.006) | 0.02 | ||
The analysis handled clustering at the participant, family and community level using random intercepts. TB: tuberculosis; MDR: multidrug-resistant; NA: not applicable. #: baseline data for patients newly diagnosed with TB disease; ¶: data for patients continuing TB treatment at the 6-month follow-up; +: contacts who were the parent or spouse of a patient in their household and assumed to have a caring role; §: controls and contacts who were not TB carers and reported having received TB treatment previously, and patients at 6-month follow-up who were no longer receiving TB treatment; ƒ: controls and contacts who reported never having received TB treatment and were not currently TB carers; ##: only calculated for patients who were receiving or were planned to receive TB treatment at the time of interview. The allocation of participants into the aforementioned groups is shown in supplementary figure S4.